Gene · 699
Papers3,725
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
681 to 700 of 3,725
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic Value of NUSAP1 and Its Correlation with Immune Infiltrates in Human Breast Cancer. | Crit Rev Eukaryot Gene Expr | 2022 | 35695609 | PubTator, text mining | PubMed |
| Gene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma. | Genes Genomics | 2022 | 35689754 | PubTator, text mining | PubMed |
| Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. | Toxicol Appl Pharmacol | 2022 | 35688186 | PubTator, text mining | PubMed |
| Genetic analysis of Caenorhabditis elegans Haspin-like genes shows that hasp-1 plays multiple roles in the germline. | Biol Open | 2022 | 35678140 | PubTator, text mining | PubMed |
| Identification of Potential Biomarkers for Pan-Cancer Diagnosis and Prognosis Through the Integration of Large-Scale Transcriptomic Data. | Front Pharmacol | 2022 | 35677427 | PubTator, text mining | PubMed |
| Identification of hub genes and biological pathways in glioma via integrated bioinformatics analysis. | J Int Med Res | 2022 | 35676807 | PubTator, text mining | PubMed |
| The Biological and Molecular Function of LINC00665 in Human Cancers. | Front Oncol | 2022 | 35664776 | PubTator, text mining | PubMed |
| SPDL1 Overexpression Is Associated With the 18F-FDG PET/CT Metabolic Parameters, Prognosis, and Progression of Esophageal Cancer. | Front Genet | 2022 | 35664322 | PubTator, text mining | PubMed |
| Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment. | Theranostics | 2022 | 35664077 | PubTator, text mining | PubMed |
| The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma. | Transl Oncol | 2022 | 35660848 | PubTator, text mining | PubMed |
| Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism. | J Exp Clin Cancer Res | 2022 | 35659274 | PubTator, text mining | PubMed |
| Tip60 acetylation of histone H3K4 temporally controls chromosome passenger complex localization. | Mol Biol Cell | 2022 | 35653296 | PubTator, text mining | PubMed |
| Zombies Never Die: The Double Life Bub1 Lives in Mitosis. | Front Cell Dev Biol | 2022 | 35646932 | PubTator, text mining | PubMed |
| AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. | iScience | 2022 | 35637734 | PubTator, text mining | PubMed |
| A Motif-Based Network Analysis of Regulatory Patterns in Doxorubicin Effects on Treating Breast Cancer, a Systems Biology Study. | Avicenna J Med Biotechnol | 2022 | 35633986 | PubTator, text mining | PubMed |
| BUB3, beyond the Simple Role of Partner. | Pharmaceutics | 2022 | 35631670 | PubTator, text mining | PubMed |
| Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). | Pharmaceuticals (Basel) | 2022 | 35631368 | PubTator, text mining | PubMed |
| Impact of Environmentally Relevant Concentrations of Bisphenol A (BPA) on the Gene Expression Profile in an In Vitro Model of the Normal Human Ovary. | Int J Mol Sci | 2022 | 35628146 | PubTator, text mining | PubMed |
| Identification of Key Prognostic Genes of Triple Negative Breast Cancer by LASSO-Based Machine Learning and Bioinformatics Analysis. | Genes (Basel) | 2022 | 35627287 | PubTator, text mining | PubMed |
| Construction of a ceRNA Network and Comprehensive Analysis of lncRNA in Hepatocellular Carcinoma. | Genes (Basel) | 2022 | 35627170 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/699/papers?page=35